TFRC and acute myeloid leukemia: Relapse after chemotherapy is a significant challenge in the treatment of acute myeloid leukemia.[18] It has been shown that VLA‐4 was highly expressed in acute myeloid leukemia cells and was closely related to chemoresistance.[17a] Therefore, a VLA‐4‐targeting peptide (V9) was genetically displayed on the surface of HFn‐Se to generate V9‐HFn‐Se that could target tumor cells through binding to TfR1 and VLA‐4 (Figure 2A).